Beyond Opioids: Five Experimental Painkillers Researchers Are Watching Closely
The Search for Safer Analgesia Continues
With the withdrawal of tanezumab from development and continued pressure to reduce opioid prescribing, the pharmaceutical industry's pipeline for non-opioid pain therapies has never mattered more. Several investigational compounds are now in Phase 2 or Phase 3 testing, each attacking pain through a different biological mechanism. Below are five candidates generating genuine interest among clinicians and researchers — along with the caveats that accompany them.
1. Suzetrigine (VX-548) — The Sodium Channel Blocker
Developed by Vertex Pharmaceuticals, suzetrigine selectively inhibits NaV2.8, a sodium channel found almost exclusively in peripheral pain-sensing neurons. By targeting a channel absent from the central nervous system, the drug aims to block pain signals without affecting normal sensation or cognition.
Phase 3 results in acute surgical pain have been encouraging, and the compound has advanced toward regulatory review for acute pain indications. Safety signals so far have been mild, though questions remain about whether efficacy is robust enough to replace opioids in severe post-surgical settings.
2. Nav1.8 Inhibitors Across the Industry
Suzetrigine is not alone in the sodium channel space. Multiple companies are developing NaV1.8 blockers for chronic neuropathic and musculoskeletal pain, including candidates in mid-stage trials for lumbosacral radiculopathy and diabetic neuropathy. The shared biology offers hope; the shared challenge is demonstrating durable relief in chronic conditions, where placebo responses run high.
3. Next-Generation NGF Antibodies
Despite tanezumab's fate, NGF inhibition has not been abandoned entirely. Several programs are exploring antibodies engineered for shorter half-lives or restricted tissue penetration, theoretically reducing the risk of rapidly progressive osteoarthritis. These remain in earlier stages, and any applicant will face the regulatory precedent set by the class's first failure.
4. Targeting the Endocannabinoid System — Without the High
A second wave of cannabinoid-adjacent therapeutics is in development, focusing on enzymes that regulate endocannabinoid signaling rather than the receptors themselves. Fatty acid amide hydrolase (FAAH) inhibitors, for example, aim to prolong the body's own pain-relieving molecules. The category suffered a major setback after a trial-related death in 2016, but refined candidates with improved safety profiles have since entered early clinical testing for chronic pain.
5. Monoclonal Antibodies for Nerve Injury Pain
Building on the success of CGRP antibodies in migraine, researchers are investigating targeted biologics for neuropathic pain conditions such as chemotherapy-induced peripheral neuropathy and sciatica. These programs are largely in Phase 2, with early signals suggesting meaningful reductions in allodynia and spontaneous pain. Long timelines are likely, but the precision of antibody-based approaches offers a safety narrative regulators may find more acceptable.
A Sober but Hopeful Outlook
No single drug will replace every use case that opioids currently fill. But the diversity of mechanisms now in late-stage development — ion channels, enzyme targets, and refined biologics — suggests the field has learned from past failures. For American patients and the clinicians who treat them, the next five years may finally deliver options that were promised a decade ago.
